- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:
– Eight Presentations on Yescarta® and Tecartus® Advance Kite’s Cell Therapy Leadership –
– New Data Highlight Magrolimab’s Potential to Alter the Tumor. | June 1, 2023